ACOR Acorda Therapeutics Inc

Price (delayed)

$4.73

Market cap

$44.88M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$15.07

Enterprise value

$149.36M

Highlights
Acorda Therapeutics's debt has decreased by 2.7% QoQ
The company's EPS rose by 48% YoY but it fell by 22% QoQ
ACOR's net income is up by 45% YoY but it is down by 27% QoQ
The company's equity fell by 33% YoY and by 13% QoQ
Acorda Therapeutics's gross profit has decreased by 23% YoY and by 6% from the previous quarter

Key stats

What are the main financial stats of ACOR
Market
Shares outstanding
9.49M
Market cap
$44.88M
Enterprise value
$149.36M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.22
Price to sales (P/S)
0.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.97
Earnings
Revenue
$153.73M
EBIT
-$99.97M
EBITDA
-$60.22M
Free cash flow
-$51.29M
Per share
EPS
-$15.07
Free cash flow per share
-$5.42
Book value per share
$21.74
Revenue per share
$16.23
TBVPS
$23.74
Balance sheet
Total assets
$584.05M
Total liabilities
$377.77M
Debt
$252.91M
Equity
$206.28M
Working capital
$56.67M
Liquidity
Debt to equity
1.23
Current ratio
1.43
Quick ratio
1.25
Net debt/EBITDA
-1.73
Margins
EBITDA margin
-39.2%
Gross margin
72.9%
Net margin
-82.3%
Operating margin
-92.4%
Efficiency
Return on assets
-19.1%
Return on equity
-48.3%
Return on invested capital
-32.7%
Return on capital employed
-22.2%
Return on sales
-65%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACOR stock price

How has the Acorda Therapeutics stock price performed over time
Intraday
24.15%
1 week
28.18%
1 month
-3.47%
1 year
-1.66%
YTD
14.25%
QTD
-0.84%

Financial performance

How have Acorda Therapeutics's revenue and profit performed over time
Revenue
$153.73M
Gross profit
$112.1M
Operating income
-$142.05M
Net income
-$126.57M
Gross margin
72.9%
Net margin
-82.3%
Acorda Therapeutics's operating income has surged by 64% YoY and by 4.6% QoQ
ACOR's operating margin has surged by 59% year-on-year and by 5% since the previous quarter
ACOR's net income is up by 45% YoY but it is down by 27% QoQ
Acorda Therapeutics's net margin has increased by 37% YoY but it has decreased by 26% QoQ

Growth

What is Acorda Therapeutics's growth rate over time

Valuation

What is Acorda Therapeutics stock price valuation
P/E
N/A
P/B
0.22
P/S
0.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.97
The company's EPS rose by 48% YoY but it fell by 22% QoQ
ACOR's P/B is 120% above its last 4 quarters average of 0.1 but 78% below its 5-year quarterly average of 1.0
The company's equity fell by 33% YoY and by 13% QoQ
ACOR's price to sales (P/S) is 76% lower than its 5-year quarterly average of 1.2 but 45% higher than its last 4 quarters average of 0.2
The company's revenue fell by 13% YoY

Efficiency

How efficient is Acorda Therapeutics business performance
ACOR's ROIC has dropped by 58% since the previous quarter but it is up by 17% year-on-year
The company's return on sales rose by 47% YoY but it fell by 29% QoQ
Acorda Therapeutics's ROE has decreased by 39% from the previous quarter but it has increased by 25% YoY
Acorda Therapeutics's ROA has decreased by 35% from the previous quarter but it has increased by 25% YoY

Dividends

What is ACOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACOR.

Financial health

How did Acorda Therapeutics financials performed over time
ACOR's total assets is 55% greater than its total liabilities
Acorda Therapeutics's current ratio has decreased by 40% YoY and by 11% QoQ
ACOR's quick ratio is up by 39% from the previous quarter but it is down by 38% YoY
Acorda Therapeutics's debt is 23% higher than its equity
Acorda Therapeutics's debt to equity has soared by 50% YoY and by 13% from the previous quarter
The company's equity fell by 33% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.